Back

Transthyretin stabiliser therapy in patients with transthyretin amyloid cardiomyopathy: a systematic review and meta-analysis

30 August 2024 (08:00 - 17:30)
Organised by: Logo
Congress Presentation Part of: Cardiac amyloidosis, sarcoidosis, and inflammation Cardiotoxicity of Drugs and Other Therapies ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Mr Vitor Ribeiro

Teresina (Brazil)

8 More presentations in this session

Presentation thumbnail
Delays in diagnosis and treatment initiation of ATTR cardiac amyloidosis: a real-world data analysis
Doctor J. Vogel (Essen, DE)
Abstract Slides Video
Presentation thumbnail
Prevalence of transthyretin amyloid cardiomyopathy in patients hospitalised for heart failure with preserved ejection fraction in an LATAM center.
Mr S. Decotto (Buenos Aires, AR)
Abstract Slides Video
Presentation thumbnail
Biomarkers for monitoring patients with cardiac amyloidosis during transthyretin-stabilizer therapy
Doctor J. Vogel (Essen, DE)
Abstract Slides
Presentation thumbnail
Relationship between changes in renal function after acute phase of tafamidis administration and left ventricular diastolic function at mid-term follow-up in transthyretin cardiac amyloidosis
Ms A. Senda (Kobe, JP)
Abstract Slides
Presentation thumbnail
Prevalence of amyloidosis among patients with mild to severe aortic stenosis. Validation of screening parameters.
Doctor F. Voss (Duesseldorf, DE)
Abstract Slides

Access the full session

Session thumbnail
Cardiac amyloidosis, sarcoidosis, and inflammation

The Event

Event poster

ESC Congress 2024

30 August - 2 September 2024
You may be interested in
thumbnail
Congress Presentation
Effects of targeted transthyretin amyloid cardiomyopathy treatments on clinical outcomes a meta-analysis
thumbnail
Congress Presentation
Stabilizers of transthyretin in amyloid cardiomyopathy: a systematic review and meta-analysis.
thumbnail
Congress Presentation
Relative efficacy of tafamidis, acoramidis, patisiran and vutrisiran in patients with transthyretin cardiac amyloidosis: a network meta-analysis

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources